83.13
-0.4(-0.48%)
Currency In USD
| Previous Close | 83.53 |
| Open | 83.36 |
| Day High | 84.83 |
| Day Low | 82.67 |
| 52-Week High | 103 |
| 52-Week Low | 19.45 |
| Volume | 256,544 |
| Average Volume | 966,680 |
| Market Cap | 5.98B |
| PE | -23.09 |
| EPS | -3.6 |
| Moving Average 50 Days | 68.15 |
| Moving Average 200 Days | 47.15 |
| Change | -0.4 |
If you invested $1000 in Kymera Therapeutics, Inc. (KYMR) since IPO date, it would be worth $2,499.4 as of December 25, 2025 at a share price of $83.13. Whereas If you bought $1000 worth of Kymera Therapeutics, Inc. (KYMR) shares 3 years ago, it would be worth $3,395.83 as of December 25, 2025 at a share price of $83.13.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Dec 11, 2025 9:01 PM GMT
WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis
GlobeNewswire Inc.
Dec 11, 2025 12:00 PM GMT
Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase 2b AD trial ongoing, with data expected to be reported by mid-2027 and BREADTH Phase 2b trial in asthma
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering
GlobeNewswire Inc.
Dec 10, 2025 4:30 AM GMT
WATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the